Biofrontera Future Growth

Future criteria checks 2/6

Biofrontera is forecast to grow earnings and revenue by 57.3% and 25.4% per annum respectively while EPS is expected to grow by 64.6% per annum.

Key information

57.3%

Earnings growth rate

64.6%

EPS growth rate

Pharmaceuticals earnings growth21.5%
Revenue growth rate25.4%
Future return on equityn/a
Analyst coverage

Low

Last updated31 Aug 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:AI10 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202561-10N/AN/A1
12/31/202447-11N/A12
12/31/202336-25N/A-162
6/30/202329-23-28-28N/A
3/31/202328-14-18-18N/A
12/31/202229-1-16-16N/A
9/30/202228-12-29-29N/A
6/30/202228-26-24-24N/A
3/31/202229-29-25-25N/A
12/31/202124-38-27-27N/A
9/30/202124-23-6-6N/A
6/30/202122-10-6-6N/A
3/31/202119-10-9-9N/A
12/31/202019-11-12-12N/A
12/31/201926-11-38-38N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AI10 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AI10 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AI10 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AI10's revenue (25.4% per year) is forecast to grow faster than the German market (4.6% per year).

High Growth Revenue: AI10's revenue (25.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AI10's Return on Equity is forecast to be high in 3 years time


Discover growth companies